Literature DB >> 19157274

Changes in plasma levels of complement in patients with acute ischemic stroke.

Inimioara Mihaela Cojocaru1, M Cojocaru, R Tănăsescu, Cecilia Burcin, Adina Nicoleta Atanasiu, Ana-Maria Petrescu, Andreea Cristina Mitu, Iulia Iliescu, Laura Dumitrescu.   

Abstract

Inflammatory processes are involved in cerebral ischemia. Patients with ischemic stroke may be predisposed to marked activation of the inflammatory system. The objective was to analyze the association between the level of complement at different stages after stroke and outcome. We collected blood samples from 179 patients (81 men and 98 women, mean age 73 +/- 5.6 years) within 24 hours after ischemic stroke, within 48 to 72 hours and at hospital discharge (16 +/- 7 days) as compared to 156 healthy controls, matching ischemic stroke patients with regard to sex and age. We measured levels of total hemolytic activity of serum complement (EIA method) and of C3, C4 (nephelometric measurements). The data were evaluated using chi 2 test. Within 24 hours after ischemic stroke in 38% patients mean value of CH50 was 148.4 +/- 57 CH50 U Eq/mL (p<0.05), of C3 was 1.49 +/- 0.24 mg/L (p<0.05) and of C4 was 0.32 +/- 0.08 mg/L (p<0.05). Within 48-72 hours after ischemic stroke in 34% patients mean value of CH50 was 167 +/- 5.9 CH50 U Eq/mL (p<0.01), of C3 was 1.58 +/- 0.27 mg/L (p<0.01) and of C4 was 0.38 +/- 0.08 mg/L (p<0.01). At hospital discharge in 31% patients mean value of CH50 was 192.8 +/- 64 CH50 U Eq/mL (p<0.001), of C3 was 1.66 +/- 0.28 mg/L (p<0.001) and of C4 was 0.49 +/- 0.07 mg/L (p<0.001). Patients with ischemic stroke who had elevated complement levels (inflammatory marker) at discharge had a worse neurological disability; complement might directly contribute to vascular damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19157274

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  7 in total

1.  Combination Therapy with Low-Dose IVIG and a C1-esterase Inhibitor Ameliorates Brain Damage and Functional Deficits in Experimental Ischemic Stroke.

Authors:  Xinzhi Chen; Thiruma V Arumugam; Yi-Lin Cheng; Jong-Hwan Lee; Srinivasulu Chigurupati; Mark P Mattson; Milan Basta
Journal:  Neuromolecular Med       Date:  2018-01-03       Impact factor: 3.843

2.  High serum complement component C4 as a unique predictor of unfavorable outcomes in diabetic stroke.

Authors:  Ximeng Zhang; Jun Yin; Kai Shao; Le Yang; Wei Liu; Yiqing Wang; Shanshan Diao; Shicun Huang; Qun Xue; Jianqiang Ni; Yi Yang
Journal:  Metab Brain Dis       Date:  2021-09-04       Impact factor: 3.584

3.  Complement C3a Receptor (C3aR) Mediates Vascular Dysfunction, Hippocampal Pathology, and Cognitive Impairment in a Mouse Model of VCID.

Authors:  Kanchan Bhatia; Adam Kindelin; Muhammad Nadeem; Mohammad Badruzzaman Khan; Junxiang Yin; Alberto Fuentes; Karis Miller; Gregory H Turner; Mark C Preul; Abdullah S Ahmad; Elliott J Mufson; Michael F Waters; Saif Ahmad; Andrew F Ducruet
Journal:  Transl Stroke Res       Date:  2022-03-08       Impact factor: 6.800

4.  Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice.

Authors:  Jiwon Yang; Hye-Na Ahn; Minsun Chang; Purnima Narasimhan; Pak H Chan; Yun Seon Song
Journal:  J Neurochem       Date:  2012-12-28       Impact factor: 5.372

Review 5.  Therapeutic Modulation of the Complement Cascade in Stroke.

Authors:  Alison R Clarke; Brandon R Christophe; Anadjeet Khahera; Justin L Sim; E Sander Connolly
Journal:  Front Immunol       Date:  2019-07-30       Impact factor: 7.561

6.  Systems biology of meridians, acupoints, and chinese herbs in disease.

Authors:  Li-Ling Lin; Ya-Hui Wang; Chi-Yu Lai; Chan-Lao Chau; Guan-Chin Su; Chun-Yi Yang; Shu-Ying Lou; Szu-Kai Chen; Kuan-Hao Hsu; Yen-Ling Lai; Wei-Ming Wu; Jian-Long Huang; Chih-Hsin Liao; Hsueh-Fen Juan
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-18       Impact factor: 2.629

Review 7.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.